Pneumosil has been established through collaboration spanning over a decade among the Serum Institute, PATH and the Bill and Melinda Gates Foundation. This important achievement is aimed at improving the availability of pneumococcal conjugate vaccines and allowing low and middle-income countries to have sustainable access.
The vaccine would provide children with safe and long-lasting immunity from pneumococcal diseases. Under the pneumococcal Advance Market Commitment (AMC), the vaccine makes the Serum Institute the world’s third supplier of pneumococcal conjugate vaccines (PCV) and the first vaccine manufacturer in developing countries to enter the global PCV market.
In 2018, nearly 67,800 children under the age of 5 die from pneumococcal diseases in India each year. WHO advocates the inclusion of the Pneumococcal Conjugate Vaccine (PCV) in regular childhood immunization programs in all countries, acknowledging its widespread fatality. After this, Polysaccharide Conjugate Vaccines (PCV) work directly by preventing Streptococcus pneumonia to reduce the occurrence of pneumococcal pneumonia.
The Serum Institute is also the pharmaceutical firm that is researching and manufacturing the vaccine candidate for Oxford-AstraZeneca Covid-19 in India. In the race to locate the silver bullet, the vaccine is the frontrunner.